Open Access

Lp(a), a new lipid frontier in CV risk management & target for therapy

Event: ESC CONGRESS 2020 - The Digital Experience
Topic: Lipids
Session type: Industry Q&A session
Organised by PACE-CME, supported by Novartis and Sanofi in the form of an educational grant
Date: 29 August 2020
Time: 12:45 - 13:45

Congress Session

This content is currently on OPEN ACCESS

Sign in to view the resources

5 presentations in this session

Lp(a): The new kid in lipid management

Speaker: Professor E. Stroes (Amsterdam, NL)
Thumbnail

Lp(a) as target in cardiovascular prevention: Why worry and how to assess?

Speaker: Professor P. Kamstrup (Herlev, DK)
Thumbnail

Novel strategies to lower Lp(a) What are the emerging insights & therapies?

Speaker: Professor S. Tsimikas (San Diego, US)
Thumbnail

ASCVD risk reduction for patients with high Lp(a) in 2020: is there a role for PCSK9 inhibition?

Speaker: Professor V. Bittner (Birmingham, US)
Thumbnail

Discussion.

Speaker: Professor E. Stroes (Amsterdam, NL)
Thumbnail

5 speakers from this session

Professor Erik Stroes

Academic Medical Centre, Amsterdam (Netherlands (The))
24 presentations
0 follower

Professor Pia Kamstrup

Copenhagen University Hospital - Herlev Gentofte, Herlev (Denmark)
3 presentations
0 follower

Professor Sotirios Tsimikas

University of California San Diego, San Diego (United States of America)
6 presentations
0 follower

Professor Vera Bittner

University of Alabama at Birmingham, Birmingham (United States of America)
1 presentation
0 follower

Professor Erik Stroes

Academic Medical Centre, Amsterdam (Netherlands (The))
24 presentations
0 follower

This platform is supported by

logo Novo Nordisk